Galectin-10 As a Potential Biomarker for Eosinophilic Diseases

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2022 Oct 27

PMID 36291593

Authors

Hiroki Tomizawa

Yoshiyuki Yamada

Misaki Arima

Yui Miyabe

Mineyo Fukuchi

Haruka Hikichi

Rossana C N Melo

Takechiyo Yamada

Shigeharu Ueki

Affiliations

Soon will be listed here.

Abstract

Galectin-10 is a member of the lectin family and one of the most abundant cytoplasmic proteins in human eosinophils. Except for some myeloid leukemia cells, basophils, and minor T cell populations, galectin-10 is exclusively present in eosinophils in the human body. Galectin-10 forms Charcot-Leyden crystals, which are observed in various eosinophilic diseases. Accumulating studies have indicated that galectin-10 acts as a new biomarker for disease activity, diagnosis, and treatment effectiveness in asthma, eosinophilic esophagitis, rhinitis, sinusitis, atopic dermatitis, and eosinophilic granulomatosis with polyangiitis. The extracellular release of galectin-10 is not mediated through conventional secretory processes (piecemeal degranulation or exocytosis), but rather by extracellular trap cell death (ETosis), which is an active cell death program. Eosinophils undergoing ETosis rapidly disintegrate their plasma membranes to release the majority of galectin-10. Therefore, elevated galectin-10 levels in serum and tissue suggest a high degree of eosinophil ETosis. To date, several studies have shown that galectin-10/Charcot-Leyden crystals are more than just markers for eosinophilic inflammation, but play functional roles in immunity. In this review, we focus on the close relationship between eosinophils and galectin-10, highlighting this protein as a potential new biomarker in eosinophilic diseases.

Citing Articles

Inhibition of EETosis with an anti-citrullinated histone antibody: a novel therapeutic approach for eosinophilic inflammatory disorders.

Zwiers E, Montizaan D, Kip A, Waaijenberg K, Fichtinger P, Mathur S Front Immunol. 2025; 16:1533407.

PMID: 40051617 PMC: 11882434. DOI: 10.3389/fimmu.2025.1533407.

Characterization of Tissue Immunity Defense Factors of the Lip in Primary Dentition Children with Bilateral Cleft Lip Palate.

Ozola L, Pilmane M J Pers Med. 2024; 14(9).

PMID: 39338219 PMC: 11433168. DOI: 10.3390/jpm14090965.

Tissue levels of Alternaria allergen Alt a 1 reflect recurrence of refractory airway diseases.

Miyabe Y, Abe T, Yamada T, Endo T, Kawasaki Y, Suzuki S Allergy. 2024; 80(2):587-589.

PMID: 39244710 PMC: 11804301. DOI: 10.1111/all.16294.

Eosinophil extracellular vesicles and DNA traps in allergic inflammation.

Weihrauch T, Melo R, Gray N, Voehringer D, Weller P, Raap U Front Allergy. 2024; 5:1448007.

PMID: 39148911 PMC: 11324581. DOI: 10.3389/falgy.2024.1448007.

Beyond type 2 asthma biomarkers: risk stratification for NSAID-exacerbated respiratory disease.

Perez-Pazos J, Garcia-Sanchez A, Estravis M, Moreno-Jimenez E, Morgado N, Gomez-Garcia M ERJ Open Res. 2024; 10(4).

PMID: 39104947 PMC: 11299009. DOI: 10.1183/23120541.00909-2023.

References

Hoekstra M, Grol M, Hovenga H, Bouman K, Stijnen T, Koeter G . Eosinophil and mast cell parameters in children with stable moderate asthma. Pediatr Allergy Immunol. 1998; 9(3):143-9. DOI: 10.1111/j.1399-3038.1998.tb00361.x. View

Vermeersch P, Zachee P, Brusselmans C . Acute myeloid leukemia with bone marrow necrosis and Charcot Leyden crystals. Am J Hematol. 2007; 82(11):1029. DOI: 10.1002/ajh.20907. View

Taylor G, Ivey A, Milner B, Grimwade D, Culligan D . Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot-Leyden crystals. Int J Hematol. 2013; 98(3):267-8. DOI: 10.1007/s12185-013-1394-9. View

Lyall H, OConnor S, Clark D . Charcot-Leyden crystals in the trephine biopsy of a patient with a FIP1L1-PDGFRA - positive myeloproliferative disorder. Br J Haematol. 2007; 138(4):405. DOI: 10.1111/j.1365-2141.2007.06669.x. View

Qi S, Yan B, Liu C, Wang C, Zhang L . Predictive significance of Charcot-Leyden Crystal mRNA levels in nasal brushing for nasal polyp recurrence. Rhinology. 2019; 58(2):166-174. DOI: 10.4193/Rhin19.296. View

Wada T, Toma T, Muraoka M, Matsuda Y, Yachie A . Elevation of fecal eosinophil-derived neurotoxin in infants with food protein-induced enterocolitis syndrome. Pediatr Allergy Immunol. 2014; 25(6):617-9. DOI: 10.1111/pai.12254. View

Muniz V, Silva J, Braga Y, Melo R, Ueki S, Takeda M . Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus. J Allergy Clin Immunol. 2017; 141(2):571-585.e7. DOI: 10.1016/j.jaci.2017.07.048. View

Varricchi G, Galdiero M, Loffredo S, Lucarini V, Marone G, Mattei F . Eosinophils: The unsung heroes in cancer?. Oncoimmunology. 2018; 7(2):e1393134. PMC: 5749653. DOI: 10.1080/2162402X.2017.1393134. View

Kayaba H, Yamada Y, Cui C, Saito N, Honda K, Kobayashi Y . Expression of VLA-4 on eosinophils decreases in patients with eosinophilia. Int Arch Allergy Immunol. 2001; 125 Suppl 1:33-7. DOI: 10.1159/000053850. View

10.

Spencer L, Bonjour K, Melo R, Weller P . Eosinophil secretion of granule-derived cytokines. Front Immunol. 2014; 5:496. PMC: 4209865. DOI: 10.3389/fimmu.2014.00496. View

11.

Wu D, Yan B, Wang Y, Zhang L, Wang C . Charcot-Leyden crystal concentration in nasal secretions predicts clinical response to glucocorticoids in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019; 144(1):345-348.e8. DOI: 10.1016/j.jaci.2019.03.029. View

12.

Marichal T, Mesnil C, Bureau F . Homeostatic Eosinophils: Characteristics and Functions. Front Med (Lausanne). 2017; 4:101. PMC: 5504169. DOI: 10.3389/fmed.2017.00101. View

13.

Takeda M, Ueki S, Yamamoto Y, Nara M, Fukuchi M, Nakayama K . Hypereosinophilic syndrome with abundant Charcot-Leyden crystals in spleen and lymph nodes. Asia Pac Allergy. 2020; 10(3):e24. PMC: 7402945. DOI: 10.5415/apallergy.2020.10.e24. View

14.

Benson V, Hartl S, Barnes N, Galwey N, Van Dyke M, Kwon N . Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. Eur Respir J. 2021; 59(1). PMC: 8756293. DOI: 10.1183/13993003.04590-2020. View

15.

Davis M, Plager D, George T, Weiss E, Gleich G, Leiferman K . Interactions of eosinophil granule proteins with skin: limits of detection, persistence, and vasopermeabilization. J Allergy Clin Immunol. 2003; 112(5):988-94. DOI: 10.1016/j.jaci.2003.08.028. View

16.

Hellmark T, Ohlsson S, Pettersson A, Hansson M, Johansson A . Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis. BMC Rheumatol. 2019; 3:9. PMC: 6408823. DOI: 10.1186/s41927-019-0059-6. View

17.

Kobayashi K, Nagase H, Sugimoto N, Yamamoto S, Tanaka A, Fukunaga K . Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma. Asia Pac Allergy. 2021; 11(3):e31. PMC: 8331256. DOI: 10.5415/apallergy.2021.11.e31. View

18.

Esnault S, Fichtinger P, Barretto K, Fogerty F, Bernau K, Mosher D . Autophagy Protects against Eosinophil Cytolysis and Release of DNA. Cells. 2022; 11(11). PMC: 9180302. DOI: 10.3390/cells11111821. View

19.

Van De Kerkhof D, Scharnhorst V, Huysentruyt C, Brands-Nijenhuis A, Ermens A . Charcot-Leyden crystals in acute myeloid leukemia. Int J Lab Hematol. 2015; 37(4):e100-2. DOI: 10.1111/ijlh.12336. View

20.

Castro M, Corren J, Pavord I, Maspero J, Wenzel S, Rabe K . Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018; 378(26):2486-2496. DOI: 10.1056/NEJMoa1804092. View